# Phase 1b/2 Study of IV Sarilumab in Adult With RA

> **NCT07704580** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sanofi** · enrollment: 140 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Sarilumab, SAR153191 SC
- **DRUG:** Sarilumab, SAR153191 IV

## Key facts

- **NCT ID:** NCT07704580
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-02
- **Primary completion:** 2028-10-26
- **Final completion:** 2028-10-26
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-08-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07704580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07704580, "Phase 1b/2 Study of IV Sarilumab in Adult With RA". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07704580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*